Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 5/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7567165 | 1.00 | GBA1 (0.45) | GBA1ACES1PR4S1PR1S1PR3 | |
| SCHEMBL7132021 | 1.00 | GBA1 (0.45) | GBA1ACES1PR4S1PR1S1PR3 | |
| SCHEMBL28572785 | 0.98 | GBA1 (0.47) | GBA1ACES1PR4S1PR1S1PR3 | |
| SCHEMBL5702265 | 0.94 | GBA2 (0.45) | GBA1ACES1PR4S1PR1S1PR3 | |
| SCHEMBL5701883 | 0.94 | GBA2 (0.45) | GBA1ACES1PR4S1PR1S1PR3 | |
| SCHEMBL1381895 | 0.89 | NR1I2 (0.50) | GBA1S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL1381896 | 0.89 | NR1I2 (0.50) | GBA1S1PR4S1PR1S1PR3S1PR5 | |
| Ammonia Solution, Strong SCHEMBL8225849 | 0.88 | NR1I2 (0.49) | GBA1S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL4947692 | 0.88 | SMN1; SMN2 (0.50) | S1PR4S1PR1S1PR3S1PR5KCNH2 | |
| SCHEMBL7114016 | 0.88 | SMN1; SMN2 (0.50) | S1PR4S1PR1S1PR3S1PR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912755-B1 | THE BIORESOLUTION OF N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRAZENECA AB (SE) | 2003-06-04 | — | — | EP | claimed |
| EP-0970049-B1 | PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY ENRICHED N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRAZENECA AB (SE) | 2002-06-05 | — | — | EP | claimed |
| US-6136591-A | Bioresolution of N-acylazetidine-2-carboxylic acids | ASTRA AB (SE) | 2000-10-24 | — | — | US | claimed |
| US-6054594-A | Process for the production of enantiomerically enriched N-acylazetidine-2-carboxylic acids | ASTRA AB (SE) | 2000-04-25 | — | — | US | claimed |
| EP-0970049-A1 | PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY ENRICHED $i(N)-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | Astra Aktiebolag (SE) | 2000-01-12 | — | — | EP | claimed |
| EP-0912755-A1 | THE BIORESOLUTION OF N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | Astra Aktiebolag (SE) | 1999-05-06 | — | — | EP | claimed |
| WO-1998002568-A1 | THE BIORESOLUTION OF N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRA AKTIEBOLAG (SE) | 1998-01-22 | — | — | WO | claimed |
| WO-1998002417-A1 | PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY ENRICHED N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRA AKTIEBOLAG (SE) | 1998-01-22 | — | — | WO | claimed |
| JP-2009108079-A | PREPARATION METHOD OF ENANTIOMERICALLY ENRICHED N-ACYLAZETIDINE-2-CARBOXYLIC ACID | ASTRAZENECA AB | 2009-05-21 | — | — | JP | disclosed |
| JP-2009022270-A | BIORESOLUTION OF N-ACYLAZETIDINE-2-CARBOXYLIC ACID | ASTRAZENECA AB | 2009-02-05 | — | — | JP | disclosed |
| EP-0974670-B1 | Process for producing optically active N-substituted azetidine-2-carboxylic acid compound | SUMITOMO CHEMICAL CO (JP) | 2006-09-13 | — | — | EP | disclosed |
| US-20040171849-A1 | Process for producing optically active azetidine-2-carboxylic acid | KANEKA CORPORATION (JP) | 2004-09-02 | — | — | US | disclosed |
| EP-1415985-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AZETIDINE-2-CARBOXYLIC ACID | KANEKA CORPORATION (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1170287-B1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE N-SUBSTITUTED AZETIDINE-2-CARBOXYLIC ACIDS | KANEKA CORP (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-0912755-A1 | THE BIORESOLUTION OF N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | Astra Aktiebolag (SE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1999004015-A1 | MICROORGANISM AND ESTERASE OBTAINED THEREFROM | CHIROTECH TECHNOLOGY LIMITED (GB) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998002417-A1 | PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY ENRICHED N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRA AKTIEBOLAG (SE) | 1998-01-22 | — | — | WO | disclosed |
| WO-1998002417-A1 | PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY ENRICHED N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRA AKTIEBOLAG (SE) | 1998-01-22 | — | — | WO | disclosed |
| WO-1998002568-A1 | THE BIORESOLUTION OF N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRA AKTIEBOLAG (SE) | 1998-01-22 | — | — | WO | disclosed |
| WO-1998002568-A1 | THE BIORESOLUTION OF N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRA AKTIEBOLAG (SE) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171849-A1 | Process for producing optically active azetidine-2-carboxylic acid | HBB, ADCY2, ADCY9 | GBA1 436/4885ACE 1397/4885S1PR4 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.